NCT06758960Completed
Analysis of Biological Progression and Regression of HELLP Syndrome in Time
Biological Evolution of HELLP Syndrome
Source: ClinicalTrials.gov · Last updated 31 Mar 2026
Brief summary (registry, in English)
Prospective observational study about progression and regression of biological parameters of HELLP syndrome
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 72 (actual)
- First submitted
- 15 Dec 2024
- Start date
- 1 Jul 2023
- Primary completion date
- 31 Jul 2025
- Lead sponsor
- CHU Mohammed VI Marrakech
- NCT number
- NCT06758960
What you commit to
- Study type: Observational
- Participants enrolled: 72
- From 1 Jul 2023 to the primary completion date, 31 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who benefited from plasma exchange therapy
Other illness
- Patients whose biological presentation was attributable to other conditions, such as microangiopathies or leukemia.
Who the study is looking for
- Pregnant women who are admitted to the maternal ICU for a biological HELLP syndrome
Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Mohammed VI of Marrakech Coordinator of this site? Confirm its status | Marrakesh | Morocco | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.